Business · 17/07/2015
FDA to Host Public Meeting on Patient-Focused Drug Development for Huntington's and Parkinson's Diseases
The FDA is hosting a public meeting to gather patient perspectives on the impact of Huntington's and Parkinson's diseases on daily life and treatment approaches, as part of its performance commitments under the Prescription Drug User Fee Act (PDUFA V).
Original source language: Federal Register — Food and Drug AdministrationOpen original release →